Navigation Links
Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
Date:11/1/2008

levels of TMC435 25 mg and 75 mg represented ~10 and >30-fold excess above the HCV replicon EC50 value, respectively.

Mean reductions of HCV RNA from baseline to day seven with TMC435 alone and in triple therapy were 2.63 and 3.47 log10 IU/mL, respectively, in the 25 mg arm, and 3.43 and 4.55 log10 IU/mL in the 75 mg arm. In the 75 mg four-week triple therapy arm, no viral breakthrough was observed; 9/9 patients achieved HCV RNA below lower limit of quantification (<25 IU/mL) and 8/9 patients achieved undetectable HCV RNA (<10 IU/mL) at day 28 (RVR=89 percent).

"These data provide important information about an emerging new approach to treating HCV," said Professor and Chairman Michael Manns, Hannover Medical School, Germany. "The discovery and development of new treatments is critical to improving the standard of care for the millions of people living with this disease."

As a global virology leader committed to patient care, Tibotec uses innovative science and expertise to research, develop, and manufacture, drugs for medical conditions with an unmet need. The company has successfully launched two antiviral medications for the treatment of HIV and is now building a portfolio of novel antiviral therapies for HCV with the goal of becoming a prominent leader in the treatment of this infectious disease.

TMC435 was discovered through a drug discovery collaboration between Medivir and Tibotec. Tibotec has the right to develop and commercialize the compound throughout the world, excluding the Nordic countries. In addition to TMC435, Tibotec has another PI in phase III development for the treatment of chronic HCV infection.

"Tibotec is committed to evaluating the safety and efficacy of TMC435 in clinical studies to determine its potential use in people with HCV," said Roger Pomerantz, M.D., president of Tibotec Research and Development. "This is an important step in our mission of addressing treatment challenges of infectious diseases, in
'/>"/>

SOURCE Tibotec BVBA
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. AHF Criticizes Tibotec Over Steep Price for Newest AIDS Drug, Etravirine
2. Tibotec Conducts Two Pivotal Phase III Clinical Trials Studying TMC278 in Treatment-Naive Adults with HIV
3. Ninety-Six Week Data on Tibotec Investigational NNRTI, TMC278, Presented at AIDS 2008
4. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
5. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
6. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
9. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
10. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
11. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a leading ... announced today the appointments of Andrew ("Andy") Arno and ... of Directors. With these additions, the Asterias Board of ... independent. Andy Arno , 55, has ... He is currently Managing Director of Emerging Growth Equities, ...
(Date:8/20/2014)... , Aug. 20, 2014 The ... lauded the latest results achieved by the real-time, ... as the National Precursor Log Exchange (NPLEx), automatically ... officials track down meth offenders and make arrests. ... Kansas blocked the sale ...
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com announces ... in its catalogue: The Impact of ... http://www.reportlinker.com/p01618927/The-Impact-of-Healthcare-Reform-PPACA-On-the-US-IVD-Industry.html ... 3590) is complex legislation that affects virtually every ... provisions are beginning to take effect now. IVD ...
Breaking Medicine Technology:Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4Kansas's Stop-Sale System Achieves Significant Results In Battle Against Meth 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 3The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 4The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 5The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 6
... Solutions, Inc. (Allscripts – NASDAQ: MDRX ) ... Paul M. Black, former Chief Operating Officer of Cerner ... Senior Vice President and Chief Legal Officer for the ... immediately.  Mr. Black will serve on the Board,s Compensation ...
... Hours, or even minutes, can mean the difference between life ... of Emergency Medical Services (EMS) Week from May ... about how quick recognition of stroke symptoms and timely response ... return to full health. Stroke is the ...
Cached Medicine Technology:Allscripts Adds Two Independent Directors to Board 2Allscripts Adds Two Independent Directors to Board 3Allscripts Adds Two Independent Directors to Board 4Allscripts Adds Two Independent Directors to Board 5"Emergency Medical Services Week" Highlights Stroke Survivors and Awareness 2"Emergency Medical Services Week" Highlights Stroke Survivors and Awareness 3"Emergency Medical Services Week" Highlights Stroke Survivors and Awareness 4"Emergency Medical Services Week" Highlights Stroke Survivors and Awareness 5
(Date:8/21/2014)... HealthDay Reporter THURSDAY, Aug. 21, 2014 (HealthDay ... nearly 12 percent in the last decade, a new report ... teens using indoor tanning beds barely decreased. Both indoor tanning ... cancers, including deadly melanomas, the researchers noted. "Unfortunately, we ... reported wearing sunscreen, from 67.7 percent in 2001 to 56.1 ...
(Date:8/21/2014)... Orange, NJ. August 21, 2014. Researchers have published ... the outcomes of patients with motor complete spinal ... disparities in functioning at discharge and follow-up among ... ahead of print on August 2 by the ... (doi: 10.1016/j.apmr.2014.07.398). Findings included small but significant differences ...
(Date:8/21/2014)... 2014 CarePoint Health is proud ... Patel, MD, and Sujoy Menon, MD, have joined ... and Dr. Menon to the community. CarePoint Health’s ... imaging services to patients in Hudson County through ... Hospital and Hoboken University Medical Center. Our board ...
(Date:8/21/2014)... August 21, 2014 The Mount Sinai ... tool called RateMyHospital®, which captures real-time patient feedback and ... patient’s care. The tool, now available to admitted patients ... collects feedback regarding patient satisfaction using smartphones. , ... because it gives us the timely information we need ...
(Date:8/21/2014)... New York (PRWEB) August 21, 2014 ... Cannabis Network that a company located in Massachusetts has ... the only marijuana patient verification system in ... welcome this new entity to our growing and compassionate ... our belief that these claims are inaccurate. , ...
Breaking Medicine News(10 mins):Health News:Fewer U.S. Teens Using Sunscreen, Study Finds 2Health News:Researchers examine impact of race and ethnicity in motor complete spinal cord injury 2Health News:Two Top Radiologists Join CarePoint Health 2Health News:The Mount Sinai Hospital Expands Use of Mobile Patient Satisfaction Tool 2Health News:The Mount Sinai Hospital Expands Use of Mobile Patient Satisfaction Tool 3Health News:MarijuanaDoctors.com Responds to Massachusetts Company's Claim 2
... TOWNSHIP, Mich., Jan. 27 Financing has become a,very popular ... decade.,But long after you have had your "nip and tuck", ... looking for ways to get out of debt, and at ... surgery. , Dr. Charles Mok ...
... system chosen needs to match needs, culture of staff , , ... hospital is, the lower its rate of patient deaths and ... also saves centers money, the researchers report. , Although there ... Herrick, senior fellow at the National Center for Policy Analysis ...
... for the prevention of coronary heart disease, with ... at highest risk (ie, those with established heart ... estimation models may not be accurately achieved in ... groups whose 10-year "short-term" estimated risk seems low. ...
... Participants Control Weight Permanently , MIDLAND, Mich., Jan. 27 ... term is the challenge. With this Health Enhancement Systems ... NutriSum: Healthy Weight for Life ( ... to gain control of their weight -- and improve their ...
... Create SolutionsPITTSBURGH, Jan. 27 To ... and consultants, HM Insurance Group, a Highmark company, ... product line, which features dedicated worksite sales specialists, ... and membership management in a highly coordinated approach ...
... One in eight physicians have been inactive in the ... and most states do not require them to undergo competency ... , Because of the lack of regulation, patient safety could ... of Michigan Child Health Evaluation and Research (CHEAR) Unit and ...
Cached Medicine News:Health News:Lay Away Plan for Cosmetic Surgery 2Health News:'Wired' Hospitals Post Lower Death, Complication Rates 2Health News:'Wired' Hospitals Post Lower Death, Complication Rates 3Health News:Assessing the real risk of heart disease in young people with low short-term risks 2Health News:Thousands Look Better, Feel Better, and Have More Energy Because of NutriSum 2Health News:HM Insurance Group Launches Next Generation Worksite Product Line 2Health News:HM Insurance Group Launches Next Generation Worksite Product Line 3Health News:Most inactive physicians retain licenses, return to practice without competency review 2
The AMY method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of amylase activity in serum, plasma and urine....
The GLU method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of glucose in serum, plasma, urine and cerebrospinal fluid....
Enzymatic Clearance assay for the in vitro quantitative determination of LDL-cholesterol in human serum and plasma....
For the quantitative in vitro determination of Lipase in human serum and plasma....
Medicine Products: